Daniel Martin - Deciphera Pharmaceuticals Chief Commercial Officer
Executive
Mr. Daniel C. Martin is Chief Commercial Officer of the company since September 2018. He has more than 20 years of commercial experience within the biopharmaceutical industry with extensive background in oncology, including immunooncology. Prior to joining Deciphera, he served as Senior Vice President, Commercial at Heron Therapeutics, a commercialstage biotechnology company, from July 2017 to September 2018, and as Vice President, Marketing and Market Access at Heron, from October 2016 to July 2017. Before joining Heron, Mr. D. Martin held commercial leadership positions at Dendreon Pharmaceuticals, from May 2011 to October 2012, and at Amgen Inc., from September 2007 to May 2011, where he played lead roles in multiple U.S. and global oncology launches. Earlier in his career, Mr. D. Martin was a management consultant with Deloitte Consulting, where he advised global biopharmaceutical companies in commercial strategy and operations since 2018.
| Age | 49 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Daniel Martin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Martin against Deciphera Pharmaceuticals stock is an integral part of due diligence when investing in Deciphera Pharmaceuticals. Daniel Martin insider activity provides valuable insight into whether Deciphera Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Deciphera Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Deciphera Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Martin over a year ago Disposition of 2267 shares by Daniel Martin of Deciphera Pharmaceuticals at 15.6176 subject to Rule 16b-3 | ||
Daniel Martin over a year ago Acquisition by Daniel Martin of 38900 shares of Deciphera Pharmaceuticals at 15.92 subject to Rule 16b-3 |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2662) % which means that it has lost $0.2662 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5037) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Deciphera Pharmaceuticals LLC currently holds 25.88 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Deciphera Pharmaceuticals has a current ratio of 5.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Deciphera Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gabriele Hansen | Evotec SE ADR | N/A | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| MD MBA | Supernus Pharmaceuticals | 64 | |
| Krista Davis | ANI Pharmaceuticals | 51 | |
| Stephen Schiavo | Alkermes Plc | N/A | |
| Elizabeth Geary | Ironwood Pharmaceuticals | N/A | |
| Christian Wojczewski | Evotec SE ADR | 53 | |
| Jerad Seurer | Avadel Pharmaceuticals PLC | 51 | |
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| Jennifer PharmD | Avadel Pharmaceuticals PLC | N/A | |
| Laetitia Rouxel | Evotec SE ADR | 50 | |
| MP MBA | Amphastar P | N/A | |
| Paul Hitchin | Evotec SE ADR | N/A | |
| Darin Esq | Neurocrine Biosciences | 59 | |
| Monika Conradt | Evotec SE ADR | N/A | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Carlos Russo | Procaps Group SA | 39 | |
| David Boyer | Neurocrine Biosciences | 46 | |
| Greg Martini | Ironwood Pharmaceuticals | 36 | |
| Kyle Gano | Neurocrine Biosciences | 52 | |
Management Performance
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Stephen Ruddy, VP Officer | ||
| Kevin Brodbeck, Senior Officer | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Thomas JD, CFO VP | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |